Stock Market & Financial News
Will Atmus Filtration (ATMU) Beat Estimates Again in Its Next Earnings Report?
Atmus Filtration (ATMU) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ATMU Will Cummins (CMI) Beat Estimates Again in Its Next Earnings Report?
Cummins (CMI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CMI Why Ally Financial (ALLY) is Poised to Beat Earnings Estimates Again
Ally Financial (ALLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ALLY Will Avantor (AVTR) Beat Estimates Again in Its Next Earnings Report?
Avantor (AVTR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AVTR 
Why Corpay (CPAY) is Poised to Beat Earnings Estimates Again
Corpay (CPAY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CPAY 
Will Monster Beverage (MNST) Beat Estimates Again in Its Next Earnings Report?
Monster Beverage (MNST) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
MNST 
Will Entegris (ENTG) Beat Estimates Again in Its Next Earnings Report?
Entegris (ENTG) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ENTG 
Will Elanco Animal Health (ELAN) Beat Estimates Again in Its Next Earnings Report?
Elanco Animal Health (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ELAN 
Will Esco Technologies (ESE) Beat Estimates Again in Its Next Earnings Report?
Esco Technologies (ESE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ESE 
Sigma Lithium: Under The Radar Lithium Expansion
Sigma Lithium trades at multi-month lows despite higher lithium prices and a strong production rebound, presenting a compelling ultra-bullish opportunity. SGML targets a production ramp from 35K in Q2'26 to 72K metric tons per quarter in 2H'26, with a long-term goal of 770K metric tons by 2028, pending funding. Low production costs and robust margins—39% EBITDA and 26% net in Q1—support strong cash flow potential as output and prices rise.
LTUM 
Gentex Corporation's Doing Great, But Not Great Enough To Shift Into High Gear
Gentex Corporation remains a 'hold' as operational improvements are offset by macroeconomic headwinds and automotive sector risks. Recent revenue growth, driven by the VOXX acquisition and premium audio products, is promising but not enough for a bullish upgrade. GNTX raised 2026 revenue guidance to $2.65–$2.75 billion, with management targeting $2.80–$2.90 billion for 2027.
GNTX 
M&T Bank Remains A Top Regional Bank To Own
M&T Bank delivered strong Q2 2026 results, beating EPS and revenue expectations despite macroeconomic headwinds. MTB's net interest margin remained robust at 3.70%, with management guiding 2026 net interest income of $7.2–$7.35 billion. Loan growth was healthy, led by commercial, industrial, and real estate segments, while deposit levels stabilized with only a minor sequential dip.
MTB 
Veradermics, Incorporated (MANE) Discusses Positive Female Results From Phase II Study of VDPHL01 for Pattern Hair Loss Transcript
Veradermics, Incorporated (MANE) Discusses Positive Female Results From Phase II Study of VDPHL01 for Pattern Hair Loss Transcript
MANE 
Top 3 Crypto & Blockchain Stocks Powering the Future of Finance
Visa, Robinhood and Block are expanding across stablecoin payments, tokenized finance and bitcoin infrastructure as digital adoption broadens.
CRCW 
Can Draganfly Capitalize on the Global Shift Toward Drone Automation?
DPRO expands beyond defense with enterprise drone automation, backed by record revenue growth and broader commercial adoption opportunities.
DPRO 
AZN Inks Deal With Dizal to In-License Rights to Lung Cancer Drug
AstraZeneca is licensing Zegfrovy from Dizal in a deal worth up to $1.5B, expanding its lung cancer portfolio with a marketed EGFR therapy.
AZN 
Reasons to Retain Abbott Stock in Your Portfolio for Now
ABT is banking on emerging-market pharmaceutical growth and innovation in Nutrition, but macro pressures and currency swings remain key challenges.
ABT 
IART Stock Surges 52.1% in a Year: What's Driving the Rally?
Integra LifeSciences has climbed 52.1% in a year as growth across both segments, improved execution and transformation efforts continue to boost results.
IART 
Can ISRG Defend Its Leadership as Global Competition Intensifies?
ISRG is countering rising global robotic surgery competition with tiered platforms, AI features and a broad ecosystem focused on value over price.
ISRG 
Can Boeing Benefit From the Global Airline Fleet Renewal Cycle?
BA rides on the global fleet renewal wave as strong demand, rising production and a $576 billion backlog support its long-term commercial aircraft outlook.
BA 
IBM Q2 preview miss prompts analysts to cut estimates on softer demand
International Business Machines Corp (NYSE:IBM) drew a more cautious outlook from analysts after preliminary second quarter results missed expectations, with Bank of America and UBS citing weaker software and infrastructure demand, shifting customer capital spending priorities and delayed large deals as key challenges for the company. Bank of America noted that IBM's preliminary Q2 revenue of $17.2 billion came in below the $17.9 billion consensus estimate, while adjusted earnings per share of $2.93 missed expectations of $3.02.
IBM 
Larry Page's Fortune Rises Above $300 Billion Amid Alphabet Rally—After Buffett Takes Credit For Berkshire Hathaway Bet
Berkshire Hathaway disclosed the purchase of just over 17.8 million Alphabet shares in November, valued at $4.3 billion at the time. The investment firm expanded its bet earlier this year, adding 36.4 million more of Alphabet's Class A shares and 3.6 million Class C shares, bringing its total holdings to about 58 million shares.
GOOG 
Bitcoin's banking adoption hits 32%, according to Michael Saylor
Bitcoin now has 32% adoption among major global banks, according to an index published by Strategy. Michael Saylor, founder of the first BTC reserve company, considers this breakthrough promising but still premature.
THENA 2.0 proposal goes live for 5-day governance vote on BNB Chain
The governance vote on THENA 2.0 could significantly transform the platform's role in DeFi, impacting its strategic direction and market position. THENA 2.0 proposal goes live for 5-day governance vote on BNB Chain.
NVDA Vs. AMD: Even if Nvidia's Kyber Rack AI is Delayed, It is the Better Buy Over AMD
NVIDIA (NASDAQ: NVDA | NVDA Price Prediction) and AMD (NASDAQ: AMD) both just reported, and the results reveal two very different AI hardware businesses.
NVDA 
Google's AI search engine poses ‘unacceptable risks for kids,' bombshell report finds
Features of Google's AI-powered search engine “create unacceptable risks for kids” – including failing to detect when they are showing signs of eating disorders or suicide, according to a bombshell investigation.
GOOG 
Centrifuge expands bug bounty program to cover V3.1 upgrade, offering $250K for critical findings
Centrifuge's expanded bug bounty program underscores the increasing importance of robust security measures in decentralized finance ecosystems. Centrifuge expands bug bounty program to cover V3.1 upgrade, offering $250K for critical findings.
UGL: I Want To Buy The Dip, But This Is Not The Right Option
ProShares Ultra Gold is rated Hold due to macro uncertainty and poor YTD performance, down 22%. UGL's 2x leverage amplifies both gains and losses, with recent downside exceeding its target multiple. Gold's outlook hinges on inflation, rates, and dollar strength; current conditions favor caution over leveraged exposure.
UGL 
Bank of New York Mellon Q2 Earnings Call Highlights
Bank of New York Mellon NYSE: BNY reported sharply higher second-quarter earnings and raised its full-year outlook, citing broad-based revenue growth, stronger client activity and momentum from its revamped commercial and operating models.
BNY 
OnKure Therapeutics Spotlights Allosteric PI3Kα Drugs as 2027 IND Targets Near
OnKure Therapeutics NASDAQ: OKUR used a scientific webcast to outline its strategy for developing mutant-selective PI3Kα inhibitors, emphasizing allosteric inhibition as a potential way to improve efficacy and tolerability in cancer and vascular anomalies.
OKUR 
